Monopar Therapeutics Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +16.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.67 | $-0.62 | +7.5% | Beat | |
| Q1 FY26 | $-1.06 | $-0.46 | +56.6% | Beat | |
| Q4 FY25 | $-0.58 | $-0.61 | -5.2% | Miss | |
| Q3 FY25 | $-0.46 | $-0.48 | -4.3% | Miss | |
| Q2 FY25 | $-0.47 | $-0.35 | +25.5% | Beat | |
| Q1 FY25 | $-0.65 | $-0.38 | +41.5% | Beat | |
| Q4 FY24 | not reported | $-2.23 | not reported | not reported | |
| Q3 FY24 | $-0.46 | $-0.37 | +19.6% | Beat | |
| Q2 FY24 | $-0.09 | $-0.10 | -11.1% | Miss | |
| Q1 FY24 | $-0.17 | $-0.10 | +41.2% | Beat | |
| Q4 FY23 | $-0.17 | $-0.12 | +29.4% | Beat | |
| Q3 FY23 | $-0.19 | $-0.14 | +26.3% | Beat |
Back to MNPR overview · MNPR holders · MNPR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.